RPT 2950
Alternative Names: RPT-2950Latest Information Update: 27 Jun 2025
At a glance
- Originator ROME Therapeutics
- Class Skin disorder therapies
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Autoimmune disorders; Cutaneous lupus erythematosus; Dermatomyositis; Neurodegenerative disorders; Systemic lupus erythematosus
Most Recent Events
- 27 Jun 2025 Clinical trials in Neurodegenerative disorders, Dermatomyositis, Cutaneous lupus erythematosus, Systemic lupus erythematosus, Autoimmune disorders (unspecified route) (ROME Therapeutics pipeline, June 2025)
- 12 Sep 2023 ROME Therapeutics plans a phase I trial for Autoimmune disorders
- 09 Mar 2023 Preclinical trials in Autoimmune disorders in USA (unspecified route)